Last reviewed · How we verify
Alemtuzumab s.c.
CD52-targeting monoclonal antibody
CD52-targeting monoclonal antibody Used for Chronic lymphocytic leukemia.
At a glance
| Generic name | Alemtuzumab s.c. |
|---|---|
| Sponsor | German CLL Study Group |
| Drug class | Monoclonal antibody |
| Target | CD52 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Alemtuzumab is a monoclonal antibody that targets the CD52 antigen on the surface of lymphocytes, leading to their depletion and immunosuppression.
Approved indications
- Chronic lymphocytic leukemia
Common side effects
- Infections
- Thrombocytopenia
- Neutropenia
Key clinical trials
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) (PHASE1)
- Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) (PHASE1, PHASE2)
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) (PHASE2)
- Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine (PHASE2)
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
- Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) (PHASE2)
- Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab s.c. CI brief — competitive landscape report
- Alemtuzumab s.c. updates RSS · CI watch RSS
- German CLL Study Group portfolio CI